Patent · US Active

Method of treating cancer by administering chimeric antigen receptor comprising anti-GCC antibody

US9662405B2 · kind B2 · utility

10Cited by

74References

5Claims

0Family size

Assignee

Thomas Jefferson University · US

Inventors

Scott A. Waldman · Ardmore, US
Michael S. Magee · Philadelphia, US
Adam E. Snook · Chester, US

Key dates

Filing date	Oct 9, 2015
Grant date	May 30, 2017
Priority date	—
Expiry date	Oct 9, 2035

Classification

Technology area (CPC G)Physics
CPC primaryG01N2333/988
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Antibodies and antigen-binding fragments of antibodies that bind GCC are disclosed. In some embodiments, the antibodies are humanized, chimeric or human. Nucleic acids and vectors encoding the antibodies or portions thereof, recombinant cells that contain the nucleic acids, and compositions comprising the antibodies or antigen-binding fragments are also disclosed. The invention also provides therapeutic and diagnostic methods utilizing the antibodies and antigen-binding.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.